Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.
about
Cardiac risk in the treatment of breast cancer: assessment and management.Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast CenterPooled analysis of cardiac safety in patients with cancer treated with pertuzumab.Optimizing the management of HER2-positive early breast cancer: the clinical reality.HER2 signaling pathway and trastuzumab cardiotoxicity.Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patientsCardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study.Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort studyA recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.HER2-positive male breast cancer: an update.Echocardiographic signs of right ventricle changes after Trastuzumab treatment in breast cancer patients with erb-2 overexpression.Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?Chemotherapy-induced cardiomyopathy.Role of echocardiography in cancer care.Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge.Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively.Breast cancer therapy-associated cardiovascular disease.Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool?Cardio-oncology: the Nuclear Option.Lack of uniformity in cardiac assessment during trastuzumab therapy.The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment.Trastuzumab: a cardiologist's perspective.Imaging and chemotherapy cardiotoxicity: A long-playing story still seeking precision and improved outcomes/management data.First annual Canadian Cardiac Oncology Network conference.Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
P2860
Q28081385-496D3487-EDA4-443D-BF1B-498C3F0BBB82Q30358689-C11BEFBC-9C31-44A4-A971-99698B80CEAEQ33800955-FBFDC63B-C908-4FEF-B426-1E054D0541BAQ33930241-ACCDB834-179A-4889-BF05-289ABDD0BA65Q34035460-F0171E0A-D542-4DCD-BD10-26F3329E7652Q34328064-BDCC50F7-1850-444B-A985-E22F29842ACDQ34625462-B69DEE11-CDA6-4644-85D6-C724D4B19526Q34975825-F7AB8E4B-D95B-42B4-921F-A49CA90D7399Q35990409-F96620F7-7DEF-47F6-86CD-6EC61D96497DQ36207305-BE211913-593A-4CF1-964E-0D054A3418EBQ36294169-FA3EB6E9-984C-4048-B603-D1D0FA520FFFQ36551901-41EDC6AA-6F85-4E57-9F9F-126FDC136577Q36887091-93F169D2-D98D-4E4B-A9ED-D340937392BDQ36900970-4EB8045F-E080-442A-9A8B-696ECAF88EF7Q37052843-54753DF9-7C4B-4D1B-9A34-AF065A87FD46Q37163787-AED8B057-9E2B-4DF7-984F-45A8238966FBQ37355586-41445161-DF5B-49F2-842D-E2340335A1E7Q37680612-BA5E8D83-6CF3-49C9-BED6-2BBF07C4A4B6Q37801220-E36BB83F-4257-4298-9569-8F8B5E532F61Q37811648-3155E81A-F85F-485C-ACD1-51161187ABECQ37867085-E90A2570-9208-465A-9350-DD418A03A30CQ37874172-BA056B8D-31E6-4762-A242-B8C6951246F2Q37973320-83FD3F77-9910-489B-9DBF-D06D408B6BCFQ38097736-93EB46BB-22B9-4E04-8960-924E49983CC4Q38645182-2A1108AC-F099-4DAA-B391-F8F249B14F8CQ38735433-74B8492C-43CD-49D1-BEE5-10504C65602BQ38982319-B6CA7910-D4D7-48CD-AC88-5D8DFA3E8687Q39185620-B172EF6E-0590-42D9-BA41-7261A1290EB2Q39746124-FBCC77E5-E26D-4EE1-96A3-3CC48D022E7EQ40420807-E5244412-0B47-4347-BB43-8B8617E595B2Q41686228-5716ADBB-B6F7-40CE-B4A8-D7288DA216F7Q41704131-CDB79C28-CAD9-4F63-B7CF-8965403DC07FQ43045832-63959CB0-B7AA-447F-AFB2-19FBEFA7581EQ44046843-6ECDEC5A-E332-43A3-861C-EB558014BB12Q45917757-BDC04F8F-51A7-4828-BA70-CA1D7D53A3E1Q46821591-7231E77B-C00F-41C3-A47F-955E0A4E230BQ52982588-3AFA8E8A-3DFA-4ADF-A498-1085E8447226Q53402025-1618C197-CB31-40B8-A89A-EC5C5642847DQ58614608-887B6C4A-8B37-418C-AC89-A7E94298013B
P2860
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Cardiac management during adju ...... ian Trastuzumab Working Group.
@ast
Cardiac management during adju ...... ian Trastuzumab Working Group.
@en
type
label
Cardiac management during adju ...... ian Trastuzumab Working Group.
@ast
Cardiac management during adju ...... ian Trastuzumab Working Group.
@en
prefLabel
Cardiac management during adju ...... ian Trastuzumab Working Group.
@ast
Cardiac management during adju ...... ian Trastuzumab Working Group.
@en
P2093
P2860
P356
P1433
P1476
Cardiac management during adju ...... dian Trastuzumab Working Group
@en
P2093
A Paterson
L Provencher
M B Sawyer
P2860
P356
10.3747/CO.2008.199
P577
2008-01-01T00:00:00Z